About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.Stay Connected
My Profile
I am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
April 2024 M T W T F S S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Twitter List
Legislative Tracking Tools
Category Archives: Pharma Industry Image
Boehringer Ingelheim Announces Cooperation with HISOAR in China
It is poetic that following the close of the Olympics in Beijing – an event that went very well in spite of all the worries leading up to it – that Boehringer Ingelheim announces a cooperation deal with a Chinese … Continue reading
Posted in Drug Safety, Pharma Industry Image
Comments Off on Boehringer Ingelheim Announces Cooperation with HISOAR in China
Pfizer Changes Its Funding of Continuing Medical Education in the U.S.
Last week I posted a tweet about Pfizer’s announcement that it is going to change the way it funds continuing medical education in the United States. I put the news out in a tweet, because I didn’t have time for … Continue reading
Posted in Pharma Industry Image
1 Comment
Pharma Philanthropy
In the past month, I’ve written a good deal about the reforms that are taking shape here in Washington aimed at the industry and the FDA. One suggestion I had was for industry to start thinking ahead of the curve … Continue reading
Posted in Pharma Industry Image
Comments Off on Pharma Philanthropy
As Storm Clouds Gather….
There is little doubt that the pharmaceutical and biotechnology industries are in for a tough time in the coming months through the election cycle and beyond. The breadth and depth of investigations and inquiries coming from Capitol Hill, by members … Continue reading
Posted in Pharma Industry Image
Comments Off on As Storm Clouds Gather….
When it All Goes Bad – Crisis Communications During Tough Times
We all have a bad time of it some of the time. Sometimes a confluence of events just throws us off our game. It isn’t just one bad piece of news, it is one after another and your very character … Continue reading
Posted in Crisis Communications, Pharma Industry Image
1 Comment